Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

Immatics biotechnologies

Biotech & Life Sciences · Tübingen, Germany · Founded 2000 Thoroughbred

Combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets

Valuation
$941M
Market cap · May/2026
Revenue
$53M
Latest reported FY

Investors

17 investors on Immatics biotechnologies's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage
Grazia Equity
Wellington Partners
L-Bank
3i Group
EMBL Ventures
Vinci Capital
Series B+ 11 investors entered at this stage
AT Impf GmbH
Amgen
DH Capital
Bristol-Myers Squibb
Swisscom Ventures
Celgene
MIG Capital
b2venture
KfW
dievini Hopp Biotech holding
Dezima Pharma

Global footprint

Where Immatics biotechnologies has talent and traffic

AI talent share
2.2% of workforce is AI talent
(14 of 627 staff)
Core AI60.96%
Other AI81.28%
Non-AI workforce61397.77%
Workforce by country
7 countries with
team presence
🇩🇪 Germany55.9%
🇺🇸 United States42.8%
🇨🇭 Switzerland0.4%
🇳🇱 Netherlands0.2%
🇮🇳 India0.2%
Top 5 of 7 shown
Web traffic by country
48K monthly visits
across markets
🇺🇸 United States85%
🇩🇪 Germany9.8%
🇬🇧 United Kingdom2.1%
🇮🇳 India2.1%
🇨🇦 Canada0.8%
Top 5 markets shown

Market sentiment

What the market is saying about Immatics biotechnologies

An AI-synthesized read of the highest-engagement posts about Immatics biotechnologies on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Immatics biotechnologies on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.